Medical Dynamics

• EU Generics Makers Demand “Clear, Open Market” (PharmaTimes)
• Sanofi-aventis, Minsheng Pharma Ink Deals to Form New Consumer Healthcare JV – Quick Facts (RTT News)
• Philippines to Announce Second Drug Price-Cut List (Bloomberg)
• AstraZeneca Cuts 8,000 jobs, No Big M&A Planned (PharmaTimes)

Read the rest of this entry »

• AZ Posts 23% Rise in 2009 Core Profit (PharmaTimes)
• P&G’s Product and Stock Prices Take Stage (The Wall Street Journal)
• Merck Granted European Approval for New Fertility Treatment ELONVA (TradingMarkets)
• EMA Calls for Opinions on its Road Map 2015 (PharmaTimes)

Read the rest of this entry »

• Novartis Profits Soar as Vasella Steps Down as CEO (PharmaTimes)
• MHRA Warns Of Internet Sales Of Counterfeit Alli (Pharmaceutical Business Review)
• Novartis Incoming CFO: No Plan For New Cost-Cutting Program (The Wall Street Journal)
• Bristol-Myers Squibb announces EU approval of ORENCIA (Zenopa)

Read the rest of this entry »

• China Agrees to Open Up Market for Indian Drugmakers (PharmaTimes)
• A Fibromyalgia Drug That Improves Sleep Quality More Than Pfizer’s Lyrica Would Earn Sizeable Patient Share in the U.S. and Europe (PR Newswire)
• Alcon Investor Expects Novartis to Raise Offer (Reuters)
• EMA’s First “compassionate use” Opinion is for Tamiflu (PharmaTimes)

Read the rest of this entry »

• Abbott Suspends Diet Drug Sales After EMEA Request (PharmaTimes)
• Big Pharma Faces Tougher 2010 Despite US Boost (Reuters)
• SkyePharma Suffers as FDA Turns Down Flutiform NDA (PharmaTimes)
• Novartis Receives Japanese Approval For Three New Medicines (New Statesmen)

Read the rest of this entry »

• Novartis Sneaks Ahead in Race to Deliver MS Pills (PharmaTimes)
• GSK Gives Price Pledge on Experimental Malaria Vaccine (Financial Times)
• Merck HIV Drug from Schering Merger Fails Trials (Reuters)
• Pharma Cuts in Early In-House R&D is Clever Move – Analysts (PharmaTimes)

Read the rest of this entry »

• Incoming EU Health Chief Pledges Action on Patient Drug Info (PharmaTimes)
• FDA Warning on Fake Versions of GSK’s Weight Loss Drug (PharmaTimes)
• J&J Recalls More Products for Contamination (Securing Pharma)
• FDA Extends Review Period for Tarceva Application for First-Line Maintenance Use in Advanced Non-Small Cell Lung Cancer (PharmaLive)

Read the rest of this entry »

• COPD Drug Spiriva Gets FDA All-Clear (PharmaTimes)
• P&G and PFSweb to Launch E-Commerce Learning Lab (PR Newswire)
• Pharma Firms Help Haiti After Earthquake Horror (PharmaTimes)
• FDA Can’t Regulate Electronic Cigarettes (The New York Times)

Read the rest of this entry »

• US FTC urges Congress to ban “pay-for-delay” deals (PharmaTimes)
• FDA panel backs Recordati’s NAGS deficiency drug (PharmaTimes)
• Swine Flu: False Pandemic? Questions In Europe (Medical News Today)
• Amgen Cancer Push on Bone Drug May Key Stock Turnaround in 2010 (Bloomberg)

Read the rest of this entry »

• EU Demands Details of Pharma “Pay For Delay” Deals (PharmaTimes)
• European Governments Cancel Vaccine Orders (The Wall Street Journal)
• Glaxo Sees Little Generic Threat to Advair (Reuters)
• FDA Draws Back the Veil (FiercePharma Manufacturing)

Read the rest of this entry »